Please use this identifier to cite or link to this item:
Title: A miniaturized flow-through cell to evaluate skin permeation of endoxifen
Authors: Mah, C.S.
Kochhar, J.S.
Ong, P.S. 
Kang, L. 
Keywords: Breast cancer
Flow-through diffusion cell
Transdermal drug delivery
Issue Date: 30-Jan-2013
Source: Mah, C.S., Kochhar, J.S., Ong, P.S., Kang, L. (2013-01-30). A miniaturized flow-through cell to evaluate skin permeation of endoxifen. International Journal of Pharmaceutics 441 (1-2) : 433-440. ScholarBank@NUS Repository.
Abstract: Endoxifen, an anti-estrogenic agent, has been recently implicated in the use of breast cancer. Its physicochemical properties make it a good candidate for transdermal delivery. However, as an investigative drug, its limited supply makes it difficult to conduct extensive pre-formulation studies. To address this issue, a miniaturized flow-through diffusion cell has been fabricated that utilized minimal amounts of the drug for in vitro skin permeation studies. The novel flow-through cells have been validated against horizontal diffusion cells and shown to cause no noticeable damage to the applied skin, as observed by histological sectioning. The cells were also demonstrated to be useful in search of suitable enhancers for endoxifen. Endoxifen permeation using permeation enhancers was tested by using this new device and limonene was found to achieve highest flux, attaining the requirement for clinical applications. The fabricated cells can thus be useful in carrying out pre-formulation studies for expensive, new drug entities, both in industrial as well as academic research. © 2012 Elsevier B.V. All rights reserved.
Source Title: International Journal of Pharmaceutics
ISSN: 03785173
DOI: 10.1016/j.ijpharm.2012.11.011
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Feb 28, 2018


checked on Mar 5, 2018

Page view(s)

checked on Feb 25, 2018

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.